Biopharma companies are actively securing capital to advance therapeutic pipelines. Kriya Therapeutics closed a $313 million funding round focused on gene therapies addressing chronic diseases including ophthalmic and neurologic conditions. Develop Health raised $14.3 million to streamline prior authorization processes in healthcare. Calidi Biotherapeutics completed a $6.9 million public offering to support targeted genetic medicine development. These financings underscore sustained investor confidence despite industry challenges and a focus on high-impact therapeutic areas.